Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2021Open Access

SARS-CoV-2 variants: levels of neutralisation required for protective immunity

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDeborah CromerMSMegan SteainARArnold Reynaldi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cromer et al. (2021) studied this question.

synapsesocial.com/papers/6aae327beae4d833005f338bhttps://doi.org/10.1101/2021.08.11.21261876
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals2021 · 131 citations
  2. 2Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma2021 · 712 citations
  3. 3Measurement of Vaccine Direct Effects Under the Test-Negative Design2018 · 134 citations
  4. 4Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK2020 · 5,026 citations
  5. 5Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine2020 · 10,918 citations